Download PDF
Semin Thromb Hemost 2016; 42(01): 030-035
DOI: 10.1055/s-0035-1564842
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors

Maria Elisa Mancuso
1   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
,
Maria Rosaria Fasulo
1   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
› Author Affiliations
Further Information

Publication History

Publication Date:
23 November 2015 (online)

    Permissions and Reprints

Abstract

Hemophilia treatment relies upon replacement of the deficient factor to restore physiological levels in plasma. The development of inhibitors is the main complication of replacement therapy, which renders replacement therapy ineffective and requires the use of alternative hemostatic drugs known as bypassing agents. The hemostatic response to bypassing agents is different from patient to patient and even in the same patient during different bleeding episodes. Up to now, no routine laboratory test has been found suitable to monitor efficacy and safety of these drugs. The unpredictable clinical response to bypassing therapy and the lack of a monitoring laboratory tool renders surgery in inhibitor patients a big challenge for the risk of both bleeding and thromboembolic complications. The thrombin generation assay (TGA) has been proposed as a monitoring tool in this patient population on the basis of the results obtained both in vitro and ex vivo. This review aims to summarize the current published evidence on the use of TGA as a laboratory monitoring tool in patients with hemophilia complicated by inhibitors.

Keywords

hemophilia - inhibitors - thrombin generation - bypassing therapy
 

  • References

  • 1 Mannucci PM, Tuddenham EG. The hemophilias—from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 2 Chantarangkul V, Clerici M, Bressi C, Giesen PLA, Tripodi A. Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. Haematologica 2003; 88 (5) 547-554
    PubMedGoogle Scholar
  • 3 Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15 (1) 3-10
    CrossrefPubMedGoogle Scholar
  • 4 Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood 1994; 83 (1) 38-42
    PubMedGoogle Scholar
  • 5 Franchini M, Coppola A, Tagliaferri A, Lippi G. FEIBA versus NovoSeven in hemophilia patients with inhibitors. Semin Thromb Hemost 2013; 39 (7) 772-778
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10 (4) 347-351
    CrossrefPubMedGoogle Scholar
  • 7 Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13 (3) 244-248
    CrossrefPubMedGoogle Scholar
  • 8 Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15 (4) 904-910
    CrossrefPubMedGoogle Scholar
  • 9 Gringeri A, Fischer K, Karafoulidou A, Klamroth R, López-Fernández MF, Mancuso E ; European Haemophilia Treatment Standardisation Board (EHTSB). Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17 (4) 630-635
    CrossrefPubMedGoogle Scholar
  • 10 Salvagno GL, Berntorp E. Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective. Semin Thromb Hemost 2010; 36 (7) 780-790
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Hemker HC, Giesen P, Al Dieri R , et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (1) 4-15
    CrossrefPubMedGoogle Scholar
  • 12 Dargaud Y, Luddington R, Gray E , et al. Standardisation of thrombin generation test—which reference plasma for TGT? An international multicentre study. Thromb Res 2010; 125 (4) 353-356
    CrossrefPubMedGoogle Scholar
  • 13 Spronk HM, Dielis AW, Panova-Noeva M , et al. Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?. Thromb Haemost 2009; 101 (6) 1156-1162
    PubMedGoogle Scholar
  • 14 Dargaud Y, Luddington R, Baglin TP. Elimination of contact factor activation improves measurement of platelet-dependent thrombin generation by calibrated automated thrombography at low-concentration tissue factor. J Thromb Haemost 2006; 4 (5) 1160-1161
    CrossrefPubMedGoogle Scholar
  • 15 Tripodi A, Chantarangkul V, Mancuso ME, Lemma L, Clerici M, Santagostino E. Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents. J Thromb Haemost 2012; 10 (4) 716-719
    CrossrefPubMedGoogle Scholar
  • 16 Mohammed BM, Martin EJ, Salinas V, Carmona R, Young G, Brophy DF. Failure of corn trypsin inhibitor to affect the thrombin generation assay in plasma from severe hemophiliacs. J Thromb Haemost 2014; 12 (9) 1558-1561
    CrossrefPubMedGoogle Scholar
  • 17 Sultan Y, Loyer F. In vitro evaluation of factor VIII—bypassing activity of activated prothrombin complex concentrate, prothrombin complex concentrate, and factor VIIa in the plasma of patients with factor VIII inhibitors: thrombin generation test in the presence of collagen-activated platelets. J Lab Clin Med 1993; 121 (3) 444-452
    PubMedGoogle Scholar
  • 18 Turecek PL, Váradi K, Keil B , et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiol Haemost Thromb 2003; 33 (1) 16-22
    CrossrefPubMedGoogle Scholar
  • 19 Key NS, Aledort LM, Beardsley D , et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80 (6) 912-918
    PubMedGoogle Scholar
  • 20 Santagostino E, Mancuso ME, Rocino A, Mancuso G, Scaraggi F, Mannucci PM. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006; 4 (2) 367-371
    CrossrefPubMedGoogle Scholar
  • 21 Young G, Shafer FE, Rojas P, Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008; 14 (2) 287-294
    CrossrefPubMedGoogle Scholar
  • 22 Dargaud Y, Bordet JC, Lienhart A, Negrier C. Use of the thrombin generation test to evaluate response to treatment with recombinant activated factor VII. Semin Hematol 2008; 45 (2) (Suppl. 01) S72-S73
    CrossrefPubMedGoogle Scholar
  • 23 Lisman T, Adelmeijer J, Heijnen HF, de Groot PG. Recombinant factor VIIa restores aggregation of alphaIIbbeta3-deficient platelets via tissue factor-independent fibrin generation. Blood 2004; 103 (5) 1720-1727
    CrossrefPubMedGoogle Scholar
  • 24 Livnat T, Martinowitz U, Zivelin A, Seligsohn U. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma. Haemophilia 2008; 14 (4) 782-786
    CrossrefPubMedGoogle Scholar
  • 25 Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116 (25) 5734-5737
    CrossrefPubMedGoogle Scholar
  • 26 Klintman J, Berntorp E, Astermark J ; MIBS Study Group. Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A. Haemophilia 2010; 16 (1) e210-e215
    CrossrefPubMedGoogle Scholar
  • 27 Astermark J, Berntorp E, White GC, Kroner BL ; MIBS Study Group. The Malmö international brother study (MIBS): further support for genetic predisposition to inhibitor development. Haemophilia 2001; 7 (3) 267-272
    CrossrefPubMedGoogle Scholar
  • 28 Livnat T, Martinowitz U, Zivelin A, Rima D, Kenet G. A highly sensitive thrombin generation assay for assessment of recombinant activated factor VII therapy in haemophilia patients with an inhibitor. Thromb Haemost 2011; 105 (4) 688-695
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Madlener K, Gissel B, Brackmann H, Pötzsch B. The endogenous thrombin generation potential (ETP) is an accurate and rapid monitoring method for recombinant factor VIIa. Ann Hematol 2000; 79 (Suppl. 01) A46
    CrossrefPubMedGoogle Scholar
  • 30 Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99 (3) 542-547
    CrossrefPubMedGoogle Scholar
  • 31 Eichinger S, Lubsczyk B, Kollars M , et al. Thrombin generation in haemophilia A patients with factor VIII inhibitors after infusion of recombinant factor VIIa. Eur J Clin Invest 2009; 39 (8) 707-713
    CrossrefPubMedGoogle Scholar
  • 32 Dargaud Y, Béguin S, Lienhart A , et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93 (3) 475-480
    PubMedGoogle Scholar
  • 33 Ay Y, Balkan C, Karapinar DY, Akin M, Bilenoğlu B, Kavakli K. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors. Clin Appl Thromb Hemost 2013; 19 (4) 389-394
    CrossrefPubMedGoogle Scholar
  • 34 Mancuso ME, Chantarangkul V, Clerici M , et al. Thrombin generation assay in hemophilic patients with or without inhibitors undergoing orthopedic surgery. Haemophilia 2014; 20 (Suppl. 03) 10
    PubMedGoogle Scholar
  • 35 Tran HTT, Sørensen B, Bjørnsen S, Pripp AH, Tjønnfjord GE, Andre Holme P. Monitoring bypassing agent therapy - a prospective crossover study comparing thromboelastometry and thrombin generation assay. Haemophilia 2015; 21 (2) 275-283
    CrossrefPubMedGoogle Scholar